Catecholaminergic polymorphic ventricular tachycardia: From bench to bedside

Heart

Volumn 99, Issue 7, 2013, Pages 497-504

  Van Der Werf, Christian ^a   Wilde, Arthur A M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; FLECAINIDE; NADOLOL; PLACEBO;

ANDERSEN SYNDROME; ARTICLE; CALCIUM HOMEOSTASIS; CASQ2 GENE; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHROMOSOME 1Q; CHROMOSOME 7P; DIFFERENTIAL DIAGNOSIS; ELECTROCARDIOGRAM; GENE; GENE MUTATION; GENETIC SCREENING; HEART DENERVATION; HOLTER MONITORING; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KCNJ2 GENE; LONG QT SYNDROME; MOLECULAR GENETICS; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RADIOCARDIOGRAPHY; RYR2 GENE; TRDN GENE;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84875210476     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302033     Document Type: Article

References (19)

1. Leenhardt A, Lucet V, Denjoy I, et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995;91:1512-9.
2. Tester DJ, Dura M, Carturan E, et al. A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors. Heart Rhythm 2007;4:733-9. (Pubitemid 46850614)
3. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999;34:2035-42. (Pubitemid 30002662)
4. Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200. (Pubitemid 32095402)
5. Bhuiyan ZA, van den Berg MP, van Tintelen JP, et al. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation 2007;116:1569-76. (Pubitemid 47511420)
6. Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001;69:1378-84. (Pubitemid 33124218)
7. Bhuiyan ZA, Hamdan MA, Shamsi ET, et al. A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22. J Cardiovasc Electrophysiol 2007;18:1060-6. (Pubitemid 47416570)
8. Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet 2012;21:2759-67. Epub 2012 Mar 14.
9. Cerrone M, Noujaim SF, Tolkacheva EG, et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2007;101:1039-48. (Pubitemid 350084981)
10. Jung CB, Moretti A, Schnitzler MM, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 2011;4:180-91.
11. Fatima A, Xu G, Shao K, et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem 2011;28:579-92.
12. Suetomi T, Yano M, Uchinoumi H, et al. Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca(2)release leading to catecholaminergic polymorphic ventricular tachycardia. Circulation 2011;124:682-94.
13. Tester DJ, Medeiros-Domingo A, Will ML, et al. Unexplained drownings and the cardiac channelopathies: a molecular autopsy series. Mayo Clin Proc 2011;86:941-7.
14. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009;54:2065-74.
15. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009;119:2426-34.
16. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009;15:380-3.
17. van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011;57:2244-54.
18. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 2008;358:2024-9. (Pubitemid 351656456)
19. Mohamed U, Gollob MH, Gow RM, et al. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 2006;3:1486-9. (Pubitemid 44849373)